On May 3, 2021, before market hours, AVROBIO issued a press release entitled “AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease” which announced that “AVROBIO can no longer pursue an accelerated approval pathway for AVR-RD-01 with the FAB-GT trial as currently designed[.]”
On this news, AVROBIO share prices fell $2.20 per share, or 18%, to close at $9.48 on May 3, 2021.